News archive for Structural biology and drug discovery
CNPase is an enzyme present at high levels in myelinating cells. Novel nanobody tools developed in an international collaboration were used to identify binding epitopes at atomic resolution and visualise myelin. Additionally, the nanobodies were used as intrabodies to bind to CNPase in living cells. These nanotools will be valuable for future research on myelin and its molecules.
TargetRNA is an EU Horizon funded Marie Skłodowska-Curie Action (MSCA) doctoral training network. In this network, 16 PhD students will be trained in RNA-ligand design in the context of antimicrobial drug discovery.
Check out a themed collection about RNA-ligand design in RSC Med. Chem.
The Brenk lab has co-authored a paper describing the EU-Openscreen fragment library.
The Brenk lab has published an article in which they have investigated the presence of metal-coordinating groups in screening libraries and chemical spaces. This can help with the discovery for new inhibitors for metallo enzymes.
As part of a consortium lead by the EU-Openscreen head office with the overall goal to improve the services offered by EU-Openscreen, the Brenk group has got funding to work on Ribotacs. Ribotacs are small molecules that selectively bind RNAs and a RNAse and thus lead targeted RNA degradation. We look forward to a succesfull collaboration.
Myelin is a crucial structure for the normal functioning of the vertebrate nervous system. Here, we have used multiple state-of-the-art technologies at large international research infrastructures, enabling methods not available in Norway, to obtain 3D structural information on some of the most hydrophobic protein molecules in the human body, which are responsible for the correct structure and... Read more
- December 2024 (1)
- August 2024 (1)
- May 2024 (1)
- February 2024 (1)
- January 2024 (1)
- July 2023 (1)
- September 2022 (1)